Erratum: Acquired resistance to zoledronic acid and the parallel acquisition of an aggressive phenotype are mediated by p38-MAP kinase activation in prostate cancer cells (Cell Death and Disease (2013) 4 (e641) DOI: 10.1038/cddis.2013.165);Acquired resistance to zoledronic acid and the parallel acquisition of an aggressive phenotype are mediated by p38-MAP kinase activation in prostate cancer cells

Cell Death and Disease

Volumn 4, Issue 5, 2013, Pages

  Milone, M R ^a   Pucci, B ^a   Bruzzese, F ^b   Carbone, C ^b,d   Piro, G ^a,d   Costantini, S ^a   Capone, F ^a   Leone, A ^b   Di Gennaro, E ^b   Caraglia, M ^c   Budillon, A ^a,b  

^a Centro di Ricerche Oncologiche di Mercogliano CROM   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

^d UNIVERSITY OF VERONA   (Italy)

Author keywords

Drug resistance; P38 MAPK; Prostate cancer; Zoledronic acid

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; CLODRONIC ACID; EOTAXIN; GELATINASE A; GELATINASE B; INTERLEUKIN 12; MITOGEN ACTIVATED PROTEIN KINASE P38; MYC PROTEIN; PAMIDRONIC ACID; PROTEIN BCL 2; VASCULOTROPIN; ZOLEDRONIC ACID;

ANOIKIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER RESISTANCE; CELL DIFFERENTIATION; CELL INVASION; CELL PROLIFERATION; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CROSS RESISTANCE; ENZYME ACTIVATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MALE; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN SECRETION;

EID: 84879378840     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.252     Document Type: Erratum

References (41)

1. Haas GP, Delongchamps N, Brawley OW, Wang CY, de la Roza G. The worldwide epidemiology of prostate cancer: perspectives from autopsy studies. Can J Urol 2008; 15: 3866-3871.
2. Mahon KL, Henshall SM, Sutherland RL, Horvath LG. Pathways of chemotherapy resistance in castration-resistant prostate cancer. Endocr Relat Cancer 2011; 18: R103-R123.
3. Coleman R, Gnant M, Morgan G, Clezardin P. Effects of bone-targeted agents on cancer progression and mortality. J Natl Cancer Inst 2012; 104: 1059-1067.
4. Saylor PJ, Lee RJ, Smith MR. Emerging therapies to prevent skeletal morbidity in men with prostate cancer. J Clin Oncol 2011; 29: 3705-3714.
5. Santini D, Caraglia M, Vincenzi B, Holen I, Scarpa S, Budillon A et al. Mechanisms of disease: preclinical reports of antineoplastic synergistic action of bisphosphonates. Nat Clin Pract Oncol 2006; 3: 325-338.
6. Caraglia M, D'Alessandro AM, Marra M, Giuberti G, Vitale G, Viscomi C et al. The farnesyl transferase inhibitor R115777 (Zarnestra) synergistically enhances growth inhibition and apoptosis induced on epidermoid cancer cells by Zoledronic acid (Zometa) and Pamidronate. Oncogene 2004; 23: 6900-6913.
7. Caraglia M, Marra M, Leonetti C, Meo G, D'Alessandro AM, Baldi A et al. R115777 (Zarnestra)/Zoledronic acid (Zometa) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl-2 and bad phosphorylation. J Cell Physiol 2007; 211: 533-543.
8. Caraglia M, Santini D, Marra M, Vincenzi B, Tonini G, Budillon A. Emerging anti-cancer molecular mechanisms of aminobisphosphonates. Endocr Relat Cancer 2006; 13: 7-26.
9. Rogers MJ, Crockett JC, Coxon FP, Monkkonen J. Biochemical and molecular mechanisms of action of bisphosphonates. Bone 2011; 49: 34-41.
10. Thurnher M, Nussbaumer O, Gruenbacher G. Novel aspects of mevalonate pathway inhibitors as antitumor agents. Clin Cancer Res 2012; 18: 3524-3531.
11. Kars MD, Iseri OD, Ural AU, Gunduz U. In vitro evaluation of zoledronic acid resistance developed in MCF-7 cells. Anticancer Res 2007; 27: 4031-4037.
12. Morii T, Ohtsuka K, Ohnishi H, Mochizuki K, Satomi K. Inhibition of heat-shock protein 27 expression eliminates drug resistance of osteosarcoma to zoledronic acid. Anticancer Res 2010; 30: 3565-3571.
13. Ory B, Moriceau G, Trichet V, Blanchard F, Berreur M, Redini F et al. Farnesyl diphosphate synthase is involved in the resistance to zoledronic acid of osteosarcoma cells. J Cell Mol Med 2008; 12: 928-941.
14. Ma XK, Wang L, Li Y, Yang XM, Zhao P, Tang H et al. HAb18G/CD147 cell-cell contacts confer resistance of a HEK293 subpopulation to anoikis in an E-cadherin-dependent manner. BMC Cell Biol 2010; 11: 27.
15. Wolfer A, Ramaswamy S. MYC and metastasis. Cancer Res 2011; 71: 2034-2037.
16. Brabletz T. EMT and MET in metastasis: where are the cancer stem cells? Cancer Cell 2012; 22: 699-701.
17. Merrell MA, Wakchoure S, Lehenkari PP, Harris KW, Selander KS. Inhibition of the mevalonate pathway and activation of p38 MAP kinase are independently regulated by nitrogen-containing bisphosphonates in breast cancer cells. Eur J Pharmacol 2007; 570: 27-37.
18. Kubo T, Shimose S, Matsuo T, Sakai A, Ochi M. Efficacy of a nitrogen-containing bisphosphonate, minodronate, in conjunction with a p38 mitogen activated protein kinase inhibitor or doxorubicin against malignant bone tumor cells. Cancer Chemother Pharmacol 2008; 62: 111-116.
19. Brehmer B, Biesterfeld S, Jakse G. Expression of matrix metalloproteinases (MMP-2 and-9) and their inhibitors (TIMP-1 and-2) in prostate cancer tissue. Prostate Cancer Prostatic Dis 2003; 6: 217-222.
20. Facchini G, Caraglia M, Morabito A, Marra M, Piccirillo MC, Bochicchio AM et al. Metronomic administration of zoledronic acid and taxotere combination in castration resistant prostate cancer patients: phase I ZANTE trial. Cancer Biol Ther 2010; 10: 543-548.
21. Nauseef JT, Henry MD. Epithelial-to-mesenchymal transition in prostate cancer: paradigm or puzzle? Nat Rev Urol 2011; 8: 428-439.
22. Evdokimova V, Tognon C, Ng T, Ruzanov P, Melnyk N, Fink D et al. Translational activation of snail1 and other developmentally regulated transcription factors by YB-1 promotes an epithelial-mesenchymal transition. Cancer Cell 2009; 15: 402-415.
23. Vindrieux D, Escobar P, Lazennec G. Emerging roles of chemokines in prostate cancer. Endocr Relat Cancer 2009; 16: 663-673.
24. Gonzalez-Moreno O, Lecanda J, Green JE, Segura V, Catena R, Serrano D et al. VEGF elicits epithelial-mesenchymal transition (EMT) in prostate intraepithelial neoplasia (PIN)-like cells via an autocrine loop. Exp Cell Res 2010; 316: 554-567.
25. Klinke DJ 2nd. An evolutionary perspective on anti-tumor immunity. Front Oncol 2012; 2: 202.
26. Agarwal M, He C, Siddiqui J, Wei JT, Macoska JA. CCL11 (eotaxin-1): a new diagnostic serum marker for prostate cancer. Prostate 2013; 73: 573-581.
27. Fleischmann A, Huland H, Mirlacher M, Wilczak W, Simon R, Erbersdobler A et al. Prognostic relevance of Bcl-2 overexpression in surgically treated prostate cancer is not caused by increased copy number or translocation of the gene. Prostate 2012; 72: 991-997.
28. Chuan YC, Iglesias-Gato D, Fernandez-Perez L, Cedazo-Minguez A, Pang ST, Norstedt G et al. Ezrin mediates c-Myc actions in prostate cancer cell invasion. Oncogene 2010; 29: 1531-1542.
29. Koh CM, Bieberich CJ, Dang CV, Nelson WG, Yegnasubramanian S, De Marzo AM. MYC and prostate cancer. Genes Cancer 2010; 1: 617-628.
30. Cuenda A, Rousseau S. p38 MAP-kinases pathway regulation, function and role in human diseases. Biochim Biophys Acta 2007; 1773: 1358-1375.
31. Wagner EF, Nebreda AR. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 2009; 9: 537-549.
32. Dunford JE, Rogers MJ, Ebetino FH, Phipps RJ, Coxon FP. Inhibition of protein prenylation by bisphosphonates causes sustained activation of Rac, Cdc42, and Rho GTPases. J Bone Miner Res 2006; 21: 684-694.
33. Marra M, Santini D, Meo G, Vincenzi B, Zappavigna S, Baldi A et al. Cyr61 downmodulation potentiates the anticancer effects of zoledronic acid in androgen-independent prostate cancer cells. Int J Cancer 2009; 125: 2004-2013.
34. Hanna M, Liu H, Amir J, Sun Y, Morris SW, Siddiqui MA et al. Mechanical regulation of the proangiogenic factor CCN1/CYR61 gene requires the combined activities of MRTF-A and CREB-binding protein histone acetyltransferase. J Biol Chem 2009; 284: 23125-23136.
35. Juric V, Chen CC, Lau LF. TNFalpha-induced apoptosis enabled by CCN1/CYR61: pathways of reactive oxygen species generation and cytochrome c release. PLoS One 2012; 7: e31303.
36. Phong MS, Van Horn RD, Li S, Tucker-Kellogg G, Surana U, Ye XS. p38 mitogen-activated protein kinase promotes cell survival in response to DNA damage but is not required for the G(2) DNA damage checkpoint in human cancer cells. Mol Cell Biol 2010; 30: 3816-3826.
37. Xu L, Chen S, Bergan RC. MAPKAPK2 and HSP27 are downstream effectors of p38 MAP kinase-mediated matrix metalloproteinase type 2 activation and cell invasion in human prostate cancer. Oncogene 2006; 25: 2987-2998.
38. Rokudai A, Terui Y, Kuniyoshi R, Mishima Y, Aizu-Yokota E, Sonoda Y et al. Differential regulation of eotaxin-1/CCL11 and eotaxin-3/CCL26 production by the TNF-alpha and IL-4 stimulated human lung fibroblast. Biol Pharm Bull 2006; 29: 1102-1109.
39. Kim L, Del Rio L, Butcher BA, Mogensen TH, Paludan SR, Flavell RA et al. p38 MAPK autophosphorylation drives macrophage IL-12 production during intracellular infection. J Immunol 2005; 174: 4178-4184.
40. Bruzzese F, Rocco M, Castelli S, Di Gennaro E, Desideri A, Budillon A. Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis. Mol Cancer Ther 2009; 8: 3075-3087.
41. Bruzzese F, Leone A, Rocco M, Carbone C, Piro G, Caraglia M et al. HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT. J Cell Physiol 2011; 226: 2378-2390.